This question lies outside my profession.

To ensure uniformity in modeling prostate cancer in situ, researchers should use standardized definitions of early-stage cancer, unified clinical and imaging data sources, and common modeling frameworks (e.g., mathematical or statistical). Applying consistent variables, validated parameters, and shared datasets—along with following reporting guidelines like TRIPOD or STROBE—helps improve reproducibility. Collaboration across institutions and external validation further ensures reliable, comparable models.